In Focus – 45mn
The world has seen COVID-19 vaccine development proceed with unprecedented speed and visibility, and many experts predict that some of the vaccines currently in Phase III testing around the world will soon be found to be safe and efficacious. What comes next? How will these vaccines be made, allocated and used in vaccination programs? How well will they work in real populations, and can we ever expect to see “herd immunity” from vaccination? What is the final approval pathway for vaccines first given “emergency use” designation, and will the first set of approved vaccines make it more difficult for the “next wave” of COVID-19 vaccines? These questions will be considered in the context of the return to normalcy, framing the discussion of the post-efficacy future.